The effect of danazol and the LHRH agonist analogue goserelin (Zoladex) on the biological activity of luteinizing hormone in women with endometriosis

What Was Tested

This randomized controlled trial paper looks at Goserelin and Buserelin in the context of endometriosis.

In an attempt to determine whether the suppression in oestradiol levels caused by danazol is due to an effect on the hypothalamic-pituitary axis, the researchers compared the endocrine effects of danazol with those of the LHRH (GnRH) agonist analogue goserelin.

Who Took Part

The study group was 20 women.

PubMed indexes the participants as adults, women only.

Serum levels of immunoreactive LH (I-LH), FSH, 17 beta-oestradiol (E2) and bioactive LH (B-LH) (using a mouse Leydig cell bioassay), were measured in ten and 20 women with endometriosis treated with danazol and goserelin, respectively.

How the Study Was Run

In design terms this was a randomized study.

The women were allocated by chance, so the Goserelin group and the comparison group should start out alike.

I-LH was measured both by radioimmunoassay (RIA) and immunoradiometric assay (IRMA).

What Was Measured

The subject headings attached to it are Buserelin, Danazol, Endometriosis, Estradiol, Follicle Stimulating Hormone, Goserelin and Luteinizing Hormone.

What This Means in Plain Language

The paper is a randomized study of Goserelin and Buserelin in 20 women in people with endometriosis.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 1990 (Clinical endocrinology), a journal based in England.

More context: the Goserelin compound page and the Buserelin compound page, Endometriosis research.